CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
brentuximab vedotin +1 moredrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01421667
NCT01421667Phase 2Completed
CompareCT.gov

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Seagen Inc.·interventional·Posted Aug 23, 2011·Updated Nov 28, 2016

In Brief

A Phase 2 clinical trial evaluating brentuximab vedotin and rituximab for Lymphoma, B-Cell and 3 related conditions. Completed, enrolled 176 participants across 34 sites in 2 countries.

Detailed Summary

This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2011
Enrollment StartAug 1, 2011
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.9 years ago

Interventions

brentuximab vedotindrug

1.8 mg/kg every 3 weeks by IV infusion

rituximabdrug

375 mg/m2 every 3 weeks by IV infusion